News
IMRNW
--
0.00%
--
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™
UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the comparative efficacy of Travelan® with two third party non-antibio...
GlobeNewswire · 05/09 10:00
Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer
MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated path...
GlobeNewswire · 05/06 00:22
Immuron Travelan® Global sales up 216%
Key Highlights: North American Travelan® sales up by 185% YoY in Q3 FY22Global sales up 216% YoY in Q3 FY22.YTD March 31, FY22 worldwide Travelan® sales reached AU $392K, increasing 340% YoY. MELBOURNE, Australia, April 27, 2022 (GLOBE NEWSWIRE) -- Immuron...
GlobeNewswire · 04/27 10:00
Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND) application advancesClinical trial Synopsis complete and ...
GlobeNewswire · 04/19 11:33
We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 03/25 09:21
Appointment of Paul Brennan as Non-Executive Director
MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pa...
GlobeNewswire · 03/16 13:30
Immuron Receives AUD $306,154 R&D Tax Concession Refund
MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pat...
GlobeNewswire · 01/17 11:00
Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pat...
GlobeNewswire · 01/13 11:00
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for TravelanU.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to support the Travelan clinical development effortTotal Award ...
GlobeNewswire · 01/12 11:00
BRIEF-Immuron Ltd - USU Have Initiated Manufacturing Campaign To Produce First Batches Of Investigational Medical Products In Nov 2021
reuters.com · 11/15/2021 11:08
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC products in Travelers’ Diarrhea initiatedUSU are anticipat...
GlobeNewswire · 11/15/2021 11:00
US DoD Naval Medical Research Center Clinical Update
Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration (FDA) planned for Q1 CY2022 to support Two human phase II ...
GlobeNewswire · 11/10/2021 11:00
BRIEF-Immuron Ltd Imm-124E Demonstrates Antiviral T-Cell Immunity
reuters.com · 10/08/2021 10:03
Companies Like Immuron (ASX:IMC) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 09/25/2021 00:40
Immuron Director resignation
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pat...
GlobeNewswire · 09/24/2021 03:00
Immuron planned Acquisition of R&D Vaccine Company
MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pat...
GlobeNewswire · 09/23/2021 13:00
BRIEF-Immuron Partners With Csiro To Produce New Oral Therapeutic For Clinical Evaluation
* IMMURON PARTNERS WITH CSIRO TO PRODUCE A NEW ORAL THERAPEUTIC FOR CLINICAL EVALUATION BY THE US DEPARTMENT OF DEFENSE
Reuters · 06/19/2020 10:47
BRIEF-Immuron Resolved To Relinquish Cash Payments Of Fees
* RESOLVED TO RELINQUISH CASH PAYMENTS OF FEES AND IN LIEU OF SAME RECEIVE COMMON STOCK IN CO
Reuters · 04/27/2020 00:37
Webull provides a variety of real-time IMRNW stock news. You can receive the latest news about Immuron Ltd through multiple platforms. This information may help you make smarter investment decisions.
About IMRNW
Immuron Limited is an Australia-based biopharmaceutical company. The Company is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The Company operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The Company's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The Company focused on clinical development of three drug candidates and several in early-stage preclinical development.